Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer
This study has been completed.
Sponsor:
The University of Texas Health Science Center at San Antonio
Information provided by (Responsible Party):
The University of Texas Health Science Center at San Antonio
ClinicalTrials.gov Identifier:
NCT00049062
First received: November 12, 2002
Last updated: February 19, 2013
Last verified: February 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Anastrozole may fight breast cancer by blocking the production of estrogen by the tumor cells. Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of advanced solid tumors. Combining anastrozole with ZD 1839 may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining anastrozole with ZD 1839 in treating postmenopausal women who have metastatic breast cancer that has not responded to hormone therapy.
| Condition | Intervention | Phase |
|---|---|---|
|
Breast Cancer |
Drug: anastrozole Drug: gefitinib |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Phase II And Biologic Correlative Study Investigating ARIMIDEX In Combination With IRESSA (ZD1839) In Post-Menopausal Patients With Estrogen Receptor-Positive Metastatic Breast Carcinoma Who Have Previously Failed Hormonal Therapy |
Resource links provided by NLM:
Further study details as provided by The University of Texas Health Science Center at San Antonio:
| Study Start Date: | September 2002 |
| Study Completion Date: | October 2007 |
| Primary Completion Date: | October 2007 (Final data collection date for primary outcome measure) |
OBJECTIVES:
- Determine the antitumor activity of anastrozole and ZD 1839, as measured by objective response (partial or complete) or stable disease at 6 months, in post-menopausal women with estrogen receptor-positive, hormone refractory, metastatic breast cancer.
- Determine the progression-free and overall survival of patients treated with this regimen.
- Determine the safety of this regimen in these patients.
- Determine the pharmacokinetics of this regimen in these patients.
- Correlate molecular markers with clinical benefit in patients treated with this regimen.
OUTLINE: This is an open-label, multicenter study.
Patients are stratified according to prior objective response to endocrine therapy (yes vs no).
Patients receive oral anastrozole once daily alone for 2 weeks. Patients then receive oral anastrozole and oral ZD 1839 once daily for 28 days. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients are followed at 1 month and then monthly thereafter.
PROJECTED ACCRUAL: A total of 36-78 patients (18-39 per stratum) will be accrued for this study.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
DISEASE CHARACTERISTICS:
Histologically confirmed breast cancer
- Metastatic or locally advanced unresectable disease
At least 1 measurable target lesion that has not been irradiated
- New lesions in a previously irradiated field allowed as sites of measurable disease
- Progressive disease after more than 2 months of aromatase inhibitor therapy
- No known CNS disease or unevaluated CNS symptoms suggestive of brain metastases
Hormone receptor status:
- Estrogen receptor or progesterone receptor positive
PATIENT CHARACTERISTICS:
Age
- 18 and over
Sex
- Female
Menopausal status
Post-menopausal by 1 of the following criteria:
- Age 50 and over and has not menstruated during the past year or has castrate follicle-stimulating hormone (FSH) levels (greater than 40 IU/L)
- Under age 50 and has castrate FSH levels
- Received prior bilateral oophorectomy and has castrate FSH levels
Performance status
- ECOG 0-2
Life expectancy
- At least 12 weeks
Hematopoietic
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
Hepatic
- Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- ALT or AST no greater than 2.5 times ULN (5 times ULN if liver metastases present)
Renal
- Creatinine no greater than 1.5 times ULN
Cardiovascular
- No history of congestive heart failure requiring therapy
- No ventricular arrhythmia requiring therapy
- No unstable angina pectoris
- No myocardial infarction within the past 6 months
Other
- Able to swallow oral medication
- No other malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix
- No known malabsorption condition or other condition that would impair absorption of study drug
- No active infection
- No other concurrent medical condition that would preclude study
- No known severe hypersensitivity to ZD 1839 or any excipients
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- No prior chemotherapy except in adjuvant setting
- No concurrent chemotherapy for breast cancer
Endocrine therapy
- See Disease Characteristics
- More than 30 days since other prior hormonal therapy (including hormone replacement therapy and megestrol)
- Concurrent steroids for other reasons besides skin toxicity allowed
- No other concurrent hormonal therapy (including megestrol) for breast cancer
Radiotherapy
- See Disease Characteristics
Surgery
- Recovered from prior oncologic or other major surgery
- No concurrent ophthalmic surgery
Other
- More than 30 days since prior anticancer therapy
- More than 30 days since prior non-approved or investigational drugs
- No prior epidermal growth factor receptor or HER2 blockers
- No concurrent phenytoin, carbamazepine, barbiturates, rifampicin, phenobarbital, Hypericum perforatum, or systemic retinoids
- No other concurrent investigational therapy for breast cancer
- Concurrent bisphosphonates for metastatic bone disease allowed
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00049062
Locations
| United States, Texas | |
| Cancer Therapy and Research Center | |
| San Antonio, Texas, United States, 78229 | |
Sponsors and Collaborators
The University of Texas Health Science Center at San Antonio
Investigators
| Study Chair: | Eric K. Rowinsky, MD | Cancer Therapy and Research Center, Texas |
More Information
Additional Information:
Publications:
Mita M, de Bono JS, Mita A, et al.: A phase II and biologic correlative study investigating anastrozole (A) in combination with geftinib (G) in post menopausal patients with estrogen receptor positive (ER) metastatic breast carcinoma (MBC) who have previously failed hormonal therapy. [Abstract] Breast Cancer Research and Treatment 94 (Suppl 1): A-1117, 2005.
| Responsible Party: | The University of Texas Health Science Center at San Antonio |
| ClinicalTrials.gov Identifier: | NCT00049062 History of Changes |
| Other Study ID Numbers: | CDR0000257752, CTRC-IDD-0219, CTRC-IDD-1839US, CTRC-IDD-0228 |
| Study First Received: | November 12, 2002 |
| Last Updated: | February 19, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by The University of Texas Health Science Center at San Antonio:
|
recurrent breast cancer stage IIIB breast cancer stage IIIC breast cancer stage IV breast cancer |
Additional relevant MeSH terms:
|
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Anastrozole Gefitinib Antineoplastic Agents, Hormonal |
Antineoplastic Agents Therapeutic Uses Pharmacologic Actions Aromatase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Protein Kinase Inhibitors |
ClinicalTrials.gov processed this record on May 19, 2013